1. Home
  2. ALT vs NMAI Comparison

ALT vs NMAI Comparison

Compare ALT & NMAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • NMAI
  • Stock Information
  • Founded
  • ALT 1997
  • NMAI 2021
  • Country
  • ALT United States
  • NMAI United States
  • Employees
  • ALT N/A
  • NMAI N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • NMAI Investment Managers
  • Sector
  • ALT Health Care
  • NMAI Finance
  • Exchange
  • ALT Nasdaq
  • NMAI Nasdaq
  • Market Cap
  • ALT 472.3M
  • NMAI 378.7M
  • IPO Year
  • ALT N/A
  • NMAI N/A
  • Fundamental
  • Price
  • ALT $4.55
  • NMAI $11.53
  • Analyst Decision
  • ALT Strong Buy
  • NMAI
  • Analyst Count
  • ALT 8
  • NMAI 0
  • Target Price
  • ALT $21.00
  • NMAI N/A
  • AVG Volume (30 Days)
  • ALT 2.2M
  • NMAI 74.8K
  • Earning Date
  • ALT 05-08-2025
  • NMAI 01-01-0001
  • Dividend Yield
  • ALT N/A
  • NMAI 13.14%
  • EPS Growth
  • ALT N/A
  • NMAI N/A
  • EPS
  • ALT N/A
  • NMAI 0.64
  • Revenue
  • ALT $20,000.00
  • NMAI N/A
  • Revenue This Year
  • ALT N/A
  • NMAI N/A
  • Revenue Next Year
  • ALT N/A
  • NMAI N/A
  • P/E Ratio
  • ALT N/A
  • NMAI $19.03
  • Revenue Growth
  • ALT N/A
  • NMAI N/A
  • 52 Week Low
  • ALT $3.55
  • NMAI $10.60
  • 52 Week High
  • ALT $11.16
  • NMAI $12.55
  • Technical
  • Relative Strength Index (RSI)
  • ALT 43.21
  • NMAI 45.37
  • Support Level
  • ALT $4.32
  • NMAI $10.75
  • Resistance Level
  • ALT $4.75
  • NMAI $11.55
  • Average True Range (ATR)
  • ALT 0.38
  • NMAI 0.32
  • MACD
  • ALT 0.05
  • NMAI 0.02
  • Stochastic Oscillator
  • ALT 63.22
  • NMAI 67.66

About ALT Altimmune Inc.

Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

About NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest

Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment strategy uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund may invest in equity and debt securities of any type without limit.

Share on Social Networks: